JB/CALL/IDORSIA/5.75/0.3333/20.12.24 | Real-time Bid/Ask 09:15:50 2024-06-18 EDT | ||
| 0.085 CHF / 0.095 CHF | -2.17% |
|
| Current month | -48.60% | ||
| 1 month | -48.60% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
IDORSIA LTD
Latest news about IDORSIA LTD
| Date | Price | Change |
|---|---|---|
| 24-06-17 | 0.092 | -6.12% |
| 24-06-13 | 0.098 | -4.85% |
| 24-06-12 | 0.103 | -14.17% |
| 24-06-11 | 0.12 | -3.23% |
Delayed Quote Swiss Exchange
Last update June 17, 2024 at 11:20 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | IDORSIA LTD |
| Issuer | Bank Julius Bär |
| IDIDJB | |
| ISIN | CH1276780553 |
| Date issued | 2023-07-25 |
| Strike | 5.75 CHF |
| Maturity | 2024-12-20 (185 Days) |
| Parity | 3 : 1 |
| Emission price | 0.69 CHF |
| Emission volume | N/A |
| Settlement | both |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.98 CHF |
|---|---|
| Lowest since issue | 0.092 CHF |
| Spread | 0.01 CHF |
| Spread % | 10.53% |
Company Profile
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Sector
-
Consensus: Idorsia Ltd
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
1.99
CHF
Average target price
1.692
CHF
Spread / Average Target
-14.95%
- Stock Market
- Warrants
- IDIDJB Warrant
